'Investing in a factor-based fund can be beneficial provided you have chosen the right factor.'
Group term insurance is far more cost-effective than an individual cover.
'Non-par plans returns are not market-linked. Hence, they can offer guaranteed returns.'
Investors who decide to enter medium to long-duration funds should be cognisant of the risk.
'Negotiate a longer agreement with the escalation clause fixed now.' 'This will enable you to control future cost increases.'
'Investors don't have to worry about underperformance in passive funds, which earn market-equivalent returns.'
Not just unclaimed bank deposits, there are thousands of crores of rupees locked in unclaimed shares and insurance policies lying with many institutions across India.
While equity savings funds could offer higher returns over three-five years, they would also be more volatile.
Avoid discontinuing your SIPs. Persist for at least 7-10 years.
'Banks will continue to increase FD rates to attract more deposits and meet the increasing demand for credit.'
Avoid discontinuing your SIPs. Persist for at least 7-10 years.
'Set aside around six months' monthly expenses for emergencies.' 'Keep this money in safe and liquid options, such as liquid funds and fixed deposits.'
'Continue with your SIPs to get the benefit of lower average prices in this challenging market environment.'
Be wary of co-operative banks which have historically been most vulnerable.
'The long maturity of these funds makes them well-suited for long-term financial goals such as saving for retirement or children's education or marriage.'
'While many policies say that they will cover mental illnesses, the wordings of a few still have mental illness as a permanent exclusion.' 'After the new IRDAI circular, such exclusions should go away.'
Suppose you had bought a television set that came with a one-year warranty. It breaks down two years after purchase. You can't react emotionally and say that such an expensive set should last for at least five-six years.
A term plan's premium is lower than that of a wholelife plan.
In contrast with their strong performance in 2020 and 2021, pharmaceutical and healthcare funds experienced a decline in 2022, with returns plummeting by an average 9.8 per cent. This trend has continued in the current year, with year-to-date return remaining in the negative (-4.9 per cent). In the past three months, pharma funds have been hit hard, experiencing a 7.9 per cent decline.
Before opting for this scheme, consider how EPS is calculated.
